The PROCTOR trial randomized 220 post-coronary artery bypass grafting patients with saphenous vein graft (SVG) failure to native vessel percutaneous coronary intervention (PCI) (n=108) or SVG PCI (n=112). At one-year, major adverse cardiac events occurred in 34 percent with native PCI vs 19 percent with SVG PCI (HR 2.14; P=0.006).
ALERT!
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Saphenous Vein Harvesting
December 4, 2025
December 4, 2025
This meta-analysis of eight randomized clinical trials (RCT) compared no-touch (NT) vs conventional (CON) saphenous vein (SV) harvesting in coronary bypass surgery. At a 3.7-year follow-up, NT-SV harvesting showed significantly lower graft failure rates compared to CON-SV.
October 9, 2025
The authors conducted the NEWTON-CABG CardioLink-5 trial to assess whether intensive lowering of low-density lipoprotein cholesterol (LDL-C) lowering with evolocumab reduces saphenous vein graft (SVG) failure after coronary artery bypass grafting (CABG).
July 31, 2024
In this month’s episode of The Atrium, host Dr. Alice Copperwheat speaks with Lorena Montes about saphenous vein harvesting.